Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 24, 2012, Pages 2977-2980

  Folkerd, Elizabeth J ^a   Dixon, J Michael ^b   Renshaw, Lorna ^b   A'Hern, Roger P ^c   Dowsett, Mitch ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; ESTRADIOL; ESTRONE SULFATE; LETROZOLE;

ADULT; AGED; ARTICLE; BODY MASS; CANCER PATIENT; CONTROLLED STUDY; CORRELATION ANALYSIS; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BODY MASS INDEX; BREAST NEOPLASMS; ESTROGENS; ESTRONE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; POSTMENOPAUSE; TRIAZOLES;

EID: 84865184360     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.0273     Document Type: Article

References (19)

1. Key TJ, Appleby PN, Reeves GK, et al: Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95:1218-1226, 2003 (Pubitemid 37069552)
2. Protani M, Coory M, Martin JH: Effect of obesity on survival of women with breast cancer: Systematic review and meta-analysis. Breast Cancer Res Treat 123:627-635, 2010
3. Kwan ML, Chen WY, Kroenke CH, et al: Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. Breast Cancer Res Treat 132:729-739, 2011
4. Sestak I, Distler W, Forbes JF, et al: Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: An exploratory analysis from the ATAC trial. J Clin Oncol 28:3411-3415, 2010
5. Pfeiler G, Königsberg R, Fesl C, et al: Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial. J Clin Oncol 29:2653-2659, 2011
6. Geisler J, Haynes B, Anker G, et al: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20:751- 757, 2002
7. Dixon JM, Renshaw L, Young O, et al: Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 26:1671-1676, 2008
8. Cuzick J, Sestak I, Baum M, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135-1141, 2010
9. Regan MM, Neven P, Giobbie-Hurder A, et al: Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12:1101-1108, 2011
10. Morris PG, Hudis CA, Giri D, et al: Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) 4:1021-1029, 2011
11. Bhatnagar AS: The discovery and mechanism of action of letrozole. Breast Cancer Res Treat 105:7-17, 2007 (suppl 1)
12. Lønning PE: The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann Oncol 22:503-514, 2011
13. Lonning PE, Haynes B, Straume AH, et al: Exploring breast cancer estrogen disposition: The basis for endocrine manipulation. Clin Cancer Res 17:4948-4958, 2011
14. Smith IE, Dowsett M: Aromatase inhibitors in breast cancer. N Engl J Med 348:2431-2442, 2003 (Pubitemid 36682823)
15. Dowsett M, Howell A: Breast cancer: Aromatase inhibitors take on tamoxifen. Nat Med 8:1341- 1344, 2002
16. Wakeling AE, Valcaccia B: Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens. J Endocrinol 99:455-464, 1983 (Pubitemid 14244074)
17. Powles TJ, Hickish T, Kanis JA, et al: Effect of tamoxifen on bone mineral density measured by duel-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78-84, 1996 (Pubitemid 26022463)
18. Ravdin PM, Fritz NF, Tormey DC, et al: Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 48:1026-1029, 1988 (Pubitemid 18061906)
19. Harper-Wynne CL, Sacks NP, Shenton K, et al: Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 20:1026-1035, 2002 (Pubitemid 34141847)